A Natural History Study of Participants With Potassium Sodium-Activated Channel Subfamily T Member 1 (KCNT1)-Related Epilepsy

计划入组 35 人 · 首次发布于 2021 年 6 月 11 日

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy

计划入组 55 人 · 首次发布于 2026 年 5 月 22 日

Ketogenic Diet for New-Onset Absence Epilepsy

计划入组 40 人 · 首次发布于 2020 年 2 月 18 日

KCNT1 targeting therapeutic (epilepsy)

SRXXX (Epilepsy)

KCNT1 inhibitor (Praxis/UCB)

EPILEPSY FOUNDATION OF AMERICA

United States

Korean Epilepsy Society

South Korea

Mid-Atlantic Epilepsy & Sleep Center, LLC

United States

Actio Biosciences Receives FDA Clearance and Fast Track Designation for First-in-Class KCNT1 Epilepsy Treatment

Jazz Pharmaceuticals Completes $820M Actio Biosciences Acquisition, Adding First-in-Class KCNT1 Epilepsy Candidate ABS-1230

Jazz Pharmaceuticals to Acquire Actio Biosciences for $820 Million, Securing First-in-Class KCNT1 Epilepsy Therapy ABS-1230